Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death

This study has been completed.
Sponsor:
Collaborator:
Boston Scientific Corporation
Information provided by:
University of Minnesota Physicians Heart at Fairview
ClinicalTrials.gov Identifier:
NCT00926159
First received: June 22, 2009
Last updated: August 3, 2011
Last verified: January 2011
  Purpose

Prophylactic implant of an ICD (implantable cardioverter defibrillator) for prevention of sudden cardiac death from a life-threatening heart rhythm abnormality is a standard recommendation for patients with ejection fractions (EFs) of 35% or less. The main purpose of the trial is to determine why patients who are receiving care at a community-based cardiology program and are known to have a low ejection fraction (EF) measurement of 35% or less per echocardiogram and/or cardiac nuclear scan testing are not being approached for ICD (implantable cardioverter defibrillator) implant. Additionally, other secondary purposes of the trial are: 1) to determine if these patients are or are not receiving recommendation from their provider to undergo prophylactic ICD implant 2) identify the reasons providers are not recommending ICD implant for their patients with reduced EFs 3) determine reasons patients recommended for ICD implant by their provider elect not to have the implant.


Condition
Cardiomyopathies

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: "Assessment of Appropriate ICD Implantation for Primary Prevention of Sudden Cardiac Death"

Resource links provided by NLM:


Further study details as provided by University of Minnesota Physicians Heart at Fairview:

Primary Outcome Measures:
  • Minnesota Heart Clinic Provider progress note from the first office visit after the cardiac echocardiogram or nuclear scan that qualified the patient for inclusion in the trial will be reviewed for documentation of discussion regarding ICD implant. [ Time Frame: First scheduled office visit with a Minnesota Heart Clinic Provider scheduled and conducted after the study qualifying cardiac echocardiogram or cardiac nuclear scan. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • A questionnaire will be issued/reviewed after completed by Providers to obtain reason(s) for not recommending ICD implant. [ Time Frame: Questionnaire will be issued after review of progress note identifies no documentation regarding possible ICD implant. ] [ Designated as safety issue: No ]

Enrollment: 549
Study Start Date: March 2008
Study Completion Date: November 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
ICD eligible
Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.

Detailed Description:

The implantable cardioverter defibrillator (ICD) for patients at high risk of sudden cardiac death (primary prevention) has become an accepted therapy after multiple randomized trials demonstrated the benefit consistently. After years of extensive evaluation of the trial data, Center for Medicare and Medicaid Services(CMS) has approved the national registry that is endorsed by the American College of Cardiology and Heart Rhythm Society. Thus, ICD implantation for primary prevention of sudden cardiac death is one of the most intensively evaluated, strictly regulated and closely monitored therapies.

Since the approval of expanded coverage for primary prevention by CMS along with the requirement for registry participation in early 2005, the ICD implant volume did not show an apparent increase as expected by many. Instead, a flat growth of ICD sales has been observed over the last 2 years. Several explanations have been offered by various sources. Some attribute the slow growth to the loss of confidence among the referring physicians, patients, and family members as the result of the multiple industry recalls. Others claim that only a small portion of the eligible candidates receive ICD therapy because of poor awareness of the ICD benefit among the referring physicians and the public (the Cambridge Heart Commercial). However, the Medtronic campaign to promote public awareness has had little impact on the volume of ICD implants. Another group of people suspect that the cardiologists have not paid enough attention to the patients' candidacy for ICD therapy because they tend to focus on the patients' ongoing symptoms not proactive prevention. Thus,an active screening program may identify a significant number of patients who will benefit from ICD therapy. However, there has been no comprehensive study that has evaluated the impact of active screening on the ICD implant volume, the percentage of eligible ICD patients without ICDs and the reasons for not receiving ICDs.

Majority of ICD implants in the United States are currently performed in the community-based cardiology programs. Thus a proactive program to identify ICD candidates in a community-based program may provide a good assessment on the unrealized potential benefit of ICDs for primary prevention of sudden cardiac death.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Minnesota Heart Clinic Patients with an ejection fraction of 35% or less as identified from cardiac echocardiogram and/or cardiac nuclear scan.

Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Ejection fraction of 35% or less by echocardiogram and/or cardiac nuclear scan

Exclusion Criteria:

  • Age less than 18 years
  • Patients currently enrolled in a clinical trial that would be impacted by receipt of an ICD
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00926159

Sponsors and Collaborators
University of Minnesota Physicians Heart at Fairview
Boston Scientific Corporation
Investigators
Principal Investigator: Huagui Li, MD, PhD University of Minnesota Physicians, Minnesota Heart Clinic
  More Information

No publications provided

Responsible Party: Huagui Li, M.D., PhD, University of Minnesota Physicians
ClinicalTrials.gov Identifier: NCT00926159     History of Changes
Other Study ID Numbers: Version # 3, December 4, 2009
Study First Received: June 22, 2009
Last Updated: August 3, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Minnesota Physicians Heart at Fairview:
Cardiomyopathies

Additional relevant MeSH terms:
Cardiomyopathies
Death, Sudden, Cardiac
Cardiovascular Diseases
Death
Death, Sudden
Heart Arrest
Heart Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on November 24, 2014